Clinical research about prostaglandin E1 and magnesium sulfate in the treatment of chronic pulmonary heart disease in the aggravation period
10.3760/cma.j.issn.1008-6315.2009.07.014
- VernacularTitle:前列腺素E1联合硫酸镁在肺心病急性加重期应用中的临床研究
- Author:
Guangying WEI
;
Jing LI
- Publication Type:Journal Article
- Keywords:
ProstaglandinE1;
Magnesium sulfate;
Pulmonary heart disease
- From:
Clinical Medicine of China
2009;25(7):708-710
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the curative effect and medchanism of action about prostaglandin E1 and magnesium sulfate in the treatment of chronic pulmonary heart disease in the aggravation period. Methods Fifty-three patients with chronic pulmonary heart disease in the aggravation period were accepted emergencyward in the Guangzhou Red Cross Hospital during June 2007 to May 2008,they were randomly divided into the treatment group (28 case) and control group (25 case) . Both groups were given low flux breathe in oxygen and dissipate phlegm and relieve a cough and resist infection and spasmo]ysis and calm down asthma and strive heart and diuresis colligate therapy. Mean while,patients in the treatment group,beside the colligate therapy,were treated with prostaglandin E1 10 ml and magnesium sulfate 10 ml ,the course of treatment lasted 2 weeks. Then we investigate the amelioration of clinical symptom and alteration of blood gas analysis in the two groups before and after the treatment. Results The rate of clinical efficacy were 89.3% (25/28) and 76.0% (18/25),with superiority in the treatment group (χ2=1.87,P<0.05) . Whole blood viscosity,fibrinogen,PaO2 and PaCO2 were improved in both groups,amelioration of blood gas analysis observation superiority in the treatment group compared with control group (P<0.05). Conclu-sions Prostaglandin E1 and magnesium sulfate can depress pulmonary artery pressure and abate the afterload of right ventricle,which have better treatment effect in chronic pulmonary heart disease in the aggravation period.
